A20 is highly expressed in GBM and forms an assembly complex together with TRAIL-R2 and RIP1; thus, A20 may serve as another potential therapeutic target to overcome TRAIL resistance in GBM through enhancing caspase-8 activation. This evidence concerns the gene RIPK1 and glioblastoma.